Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): study protocol of a phase 2 double-blinded randomised placebo-controlled trial
Frampton R, Snaith JR, Hocking S, et al.
Diabet Med. Pub. online 9 Jun 2024.
Leggi
Frampton R, Snaith JR, Hocking S, et al.
Diabet Med. Pub. online 9 Jun 2024.
Leggi
Winther JB, Holst JJ
Diabetes Obes Metab. Pub. online 9 Jun 2024.
Leggi
Marques P, Mavrakanas TA, Guida J, et al.
Diabetes Obes Metab. Pub. online 3 Jun 2024.
Leggi
Fureman AL, Bladh M, Carlsson A, et al.
Diabetes Technol Ther. Pub. online 6 Jun 2024.
Leggi
Witkowski M, Nemet I, Li XS, et al.
Eur Heart J. Pub. online 6 Jun 2024.
Leggi
Li X, Wang J, Zhang M, et al.
Diabetes Obes Metab. Pub. online 9 Jun 2024.
Leggi
03/06/2024
Leggi
Kitaoka K, Yano Y, Nagasu H, et al.
BMJ Open Diabetes Res Care. Pub. online 30 May 2024.
Leggi
Qu C, Zhao J, Lai J, et al.
BMC Med. Pub. online 3 June 2024.
Leggi
Singh T, Weiss A, Vehik K, et al.
Diabetologia. Pub. online 31 May 2024.
Leggi